BC PharmaCare: Your Voice



Get Involved

or

Read the Ongoing Results of this Engagement

What is this engagement about?

The Ministry of Health has two main goals for the BC PharmaCare program:

  • To cover drugs that support the health and well-being of British Columbians; and
  • To make sure that the drugs PharmaCare covers are affordable and give the best value for money.

To meet the first goal, PharmaCare covers a drug only if it has a proven record of safety and effectiveness. To meet the second goal, PharmaCare compares each drug to the drugs it already covers that treat the same condition. For example, if more than one drug provides the same health benefit, PharmaCare may cover only the drug(s) that offers the best value.

Before PharmaCare decides if it will cover a drug, the drug goes through a full review to find out if covering it aligns with the goals above. Patients, caregivers and patient groups have the opportunity to add their voices to the drug review process.

The Ministry of Health is considering the following drugs for PharmaCare coverage:

Generic name: dalbavancin

  • Brand name: Xydalba
  • Drug used for: Acute bacterial skin and skin structure infections, adults
  • Dates for Input: From Wednesday, August 31, 2022 to Wednesday, September 28, 2022, AT MIDNIGHT

Generic name: tezepelumab

  • Brand name: Tezspire
  • Drug used for: Asthma, adults and adolescents 12 years and older
  • Dates for Input: From Wednesday, August 31, 2022 to Wednesday, September 28, 2022, AT MIDNIGHT

Generic name: upadacitinib

  • Brand name: Rinvoq
  • Drug used for: Ulcerative colitis, adults
  • Dates for Input: From Wednesday, August 31, 2022 to Wednesday, September 28, 2022, AT MIDNIGHT

Generic name: guselkumab

  • Brand name: Tremfya
  • Drug used for: Psoriatic arthritis, adults
  • Dates for Input: From Wednesday, August 31, 2022 to Wednesday, September 28, 2022, AT MIDNIGHT

Generic name: lumasiran

  • Brand name: Oxlumo
  • Drug used for: Primary hyperoxaluria type 1 (PH1) in adults and pediatric patients
  • Dates for Input: From Wednesday, August 31, 2022 to Wednesday, September 28, 2022, AT MIDNIGHT

Generic name: mepolizumab

  • Brand name: Nucala
  • Drug used for: Severe chronic rhinosinusitis with nasal polyps, adults
  • Dates for Input: From Wednesday, August 31, 2022 to Wednesday, September 28, 2022, AT MIDNIGHT

To provide input, please visit our website at http://www.gov.bc.ca/bcyourvoice.

How can my contribution make a difference?

All responses that are submitted during the open consultation are sent to the Drug Benefit Council. The Council takes the public’s input into consideration when they make their drug coverage recommendations. Drugs are posted for review on an ongoing basis.

Details of the Engagement:
Date: June 6, 2017
Status: Ongoing
Location: Province-wide
Category: Health & Safety
Types: Online

Get Involved

or

Read the Ongoing Results of this Engagement